NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球阿茲海默症診斷及治療藥市場:各治療藥、診斷法、地區 - 成長,趨勢,預測(2018年∼2023年)

Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 661016
出版日期 內容資訊 英文 119 Pages
商品交期: 2-3個工作天內
價格
全球阿茲海默症診斷及治療藥市場:各治療藥、診斷法、地區 - 成長,趨勢,預測(2018年∼2023年) Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
出版日期: 2021年07月01日內容資訊: 英文 119 Pages
簡介

全球阿茲海默症診斷及治療藥市場,2017年價值71億美元,預計從2018年到2023年以6.7%的年複合成長率發展。各地區中,北美市場佔最大的佔有率。

本報告提供全球阿茲海默症診斷及治療藥市場調查,市場概要,各治療藥、診斷法、地區的市場規模的變化與預測,市場趨勢,市場佔有率,成長要素、阻礙因素以及市場機會、課題分析,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 成長要素,阻礙因素,市場機會,課題分析

  • 成長要素
    • 醫藥品開發的生物標記的投資
    • 開發平台醫藥品的開發擴大
    • 阿茲海默症的罹患率及盛行率的上升
    • 早期發現的先進診斷增加和精密醫藥品的開發
    • 新興診斷技術的崛起
  • 市場阻礙因素
    • 症狀的早期診斷的課題
    • 後期臨床試驗失敗造成的市場衰退
    • 藥物研發和醫藥品開發的替代標記的缺乏
    • 不完全的研究資金與不確實長期性的流程
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各治療藥物
    • 膽鹼酯酶抑制劑
    • NMDA受體拮抗劑
    • 其他
  • 各診斷法
    • 腦成像
    • 腦脊髓液(CSF)檢驗
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • 合併及收購分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • F. Hoffmann-La Roche
  • Novartis
  • Merck & Co.
  • Pfizer Inc
  • Eisai
  • Biogen Inc
  • Johnson & Johnson
  • Eli Lily & Co
  • Amarantus Bioscience Holdings
  • DiaGenic ASA
  • Navidea Biopharmaceuticals Holdings Inc.
  • GE Healthcare

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 53669

The Alzheimer's disease diagnostics and therapeutics market was valued at USD 6,632.82 million in 2020, and it is expected to reach approximately USD 9,073 million in 2026, registering a CAGR of nearly 5.36% during the forecast period, 2021-2026. The study titled, "Alzheimer's and Parkinson's diseases predict different COVID-19 outcomes, a UK Biobank study", published in November 2020, exhibited that patients suffering from dementia are at the highest risk of mortality from COVID-19. Hence, this is expected to create new opportunities for novel treatments and diagnosis in the market studied.

The key factors propelling the growth of this market are the increasing prevalence of chronic diseases like dementia, increasing pipeline drug development, investment in biomarkers for drug development, and increasing sophisticated diagnostics for early detection. According to the World Alzheimer Report, in 2019, around 50 million people worldwide were reported to be suffering from Alzheimer's and related dementia, and this number is further expected to reach 152 million by 2050.​

The extensive research studies being conducted related to Alzheimer's disease are further accelerating the market growth. For instance, in October 2020, ImmunoBrain Checkpoint Inc. was funded USD 1,000,000 by the Alzheimer's Association to aid the Phase 1 clinical trial for "IBC-Ab002" in the treatment of Alzheimer's. This is expected to accelerate the market growth. Also, the National Institute of Health reported that in July 2019, there were 132 agents in clinical trials for AD; 28 agents were in 42 Phase 3 trials, 74 agents were in 83 Phase 2 trials, and 30 agents were in 31 Phase 1 trials. There was an increasing number of agents in each phase compared to the 2018 pipeline. Hence, the increasing number of clinical studies for diagnosis and treatment of Alzheimer's is expected to drive the market growth.

However, high failure rates of clinical studies related to diagnosis and treatment of Alzheimer's are expected to hinder the market growth.

Key Market Trends

Cholinesterase Inhibitors are Expected to Hold the Highest Market Share in the Therapeutics Segment

Cholinesterase inhibitors are believed to have the largest market size, and they are expected to witness a high CAGR during the forecast period. During this pandemic situation, cholinesterase is being studied extensively for its safety, efficacy, and side effects in Alzheimer's patients with COVID-19 infection. As per the study titled, "Potential Novel Role of COVID-19 in Alzheimer's Disease and Preventative Mitigation Strategies", published in June 2020, the cholinergic anti-inflammatory pathway was observed to be a viable target to control inflammation and for the prevention of cytokine storm post detection of COVID-19 virus infection in Alzheimer's patients, and acetylcholinesterase inhibitors can potentially be administered as an adjunctive therapy.

Cholinesterase inhibitors can slightly delay the loss of brain function in people who have mild to moderate Alzheimer's disease. Cholinesterase inhibitors are prescribed to treat symptoms related to memory, thinking, language, judgment, and other thought processes. Some of the drugs approved by the United States Food & Drug Administration are Aricept, Exelon, and Razadyne indicated against mild to moderate Alzheimer's.

Furthermore, companies are investing in the development of new drugs. For instance, in January 2020, Corium International Inc. filed a New Drug Application (NDA) for ADLARITY (donepezil transdermal system) indicated for the treatment of Alzheimer's disease. Hence, owing to the developments, the cholinesterase inhibitors segment is expected to grow during the forecast period.

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America currently dominates the market for Alzheimer's disease diagnostics and therapeutics, and it is expected to continue its stronghold for a few more years. The United States holds the largest share of the market. However, there have been many reports of neurologic complications associated with COVID-19. The COVID-19 pandemic has also caused drastic changes in Alzheimer's patients' normal routine with social distancing and lockdowns in place in the United States. Understandably, many Alzheimer's patients have experienced a negative impact on their mental health.

The rising geriatric population is one of the key factors responsible for the market growth in this country, as the older population is at a higher risk of acquiring the disease. As per the United States Census Bureau data, in 2019, about 54 million Americans were aged 65 years and above. Furthermore, according to the Alzheimer's Association, more than 5.8 million Americans suffer from Alzheimer's disease, as of 2020. Hence, the rising geriatric population, coupled with the rising burden of the disease, is expected to boost the demand for diagnostics and treatment in this country.

The United States is considered to be the global leader in Alzheimer's disease intervention and management. According to the Alzheimer's Association, the total healthcare expenditure on patients with dementia was estimated to be USD 357,297 in 2019. Overall, the market is expected to register a healthy CAGR over the forecast period.

Furthermore, the increasing number of research studies related to the diagnosis and management of Alzheimer's disease is expected to drive the market growth. According to the National Clinical Trials Registry (NCT), in the United States, currently, there are about 144 active clinical trials under development for Alzheimer's disease across different phases. Due to the COVID-19 outbreak in the country, the number of clinical trials is expected to increase at a slow pace due to the lack of resources and patients' availability.

Competitive Landscape

The Alzheimer's disease diagnostics and therapeutics market is moderately competitive and consists of several major players. With technological advancements and product innovation, mid-size to smaller companies are expanding their market presence by introducing new technologies with better results. Companies like F. Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., and Eli Lily and Co. hold substantial shares in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Use of Biomarkers in Diagnosis and Drug Development
    • 4.2.2 Large Number of Drugs in Pipeline
    • 4.2.3 Emerging Novel Diagnostic Technologies
  • 4.3 Market Restraints
    • 4.3.1 High Failure Rates of Late-stage Drugs
    • 4.3.2 Lack of Surrogate Markers and Challenges in Early Diagnosis
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value)

  • 5.1 By Product
    • 5.1.1 Therapeutics
      • 5.1.1.1 Cholinesterase Inhibitors
      • 5.1.1.2 NMDA Receptor Antagonists
      • 5.1.1.3 Other Therapeutics
    • 5.1.2 Diagnostics
      • 5.1.2.1 Brain Imaging
      • 5.1.2.2 CFS Test for Alzheimer's Disease
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 F. Hoffmann-La Roche
    • 6.1.2 Novartis AG
    • 6.1.3 Merck & Co. Inc.
    • 6.1.4 Pfizer Inc.
    • 6.1.5 Eisai Co. Ltd
    • 6.1.6 Biogen Inc.
    • 6.1.7 Johnson & Johnson
    • 6.1.8 Eli Lilly and Company
    • 6.1.9 Lupin Limited
    • 6.1.10 Abbvie Inc (Allergan)
    • 6.1.11 Siemens Healthineers
    • 6.1.12 Zydus Cadila
    • 6.1.13 Merz Pharma
    • 6.1.14 Teva Pharmaceutical Industries Ltd
    • 6.1.15 Adamas Pharmaceuticals Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS